Loading stock data…
Abivax SA (ABVX)
$96.54-0.96 (-0.98%)
Market OpenUpdated 2:08 PM EDT
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ABIVAX Société Anonyme in the Healthcare sector is trading at $95.23 with a market capitalization of $7.2B. Wall Street consensus targets $150.73 (11 analysts), implying a +58.3% move over the next 12 months. The stock is currently 36% below its 52-week high of $148.83, remaining 14.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +58.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$56.23M↑ | -$71.65M↑ | -$80.71M↓ | -$46.50M↑ | -$47.20M |
| Net Income | -$48.47M↑ | -$81.96M↑ | -$153.36M↓ | -$48.41M↑ | -$52.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-77.33%
Volume
Today's trading volume
864,345
Recent News
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
Abivax (ABVX) Reports Positive Phase 3 Maintenance Trial Results for Obefazimod in Ulcerative Colitis
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best up and coming stocks to buy for the next 3 years. On June 1, Abivax announced positive topline results from its Phase 3 ABTECT maintenance trial for obefazimod, an oral, first-in-class miR-124 enhancer being developed for moderately to severely active ulcerative colitis. At Week 44, both […]
Abivax (ABVX) Reports Q1 2026 Financial Results with Cash Runway Extending Through 2027
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best young stocks to invest in according to hedge funds. On May 22, Abivax reported Q1 2026 financial results, highlighting a solid cash position of €491.6 million, which provides a runway into Q4 2027. R&D expenses rose to €49.5 million, largely driven by ongoing trials for new […]
European Value Stocks Trading Below Estimated Intrinsic Values June 2026
As European markets navigate a period of uncertainty marked by economic contractions and fluctuating retail sales, investors are increasingly focused on identifying opportunities that offer attractive valuations. In this context, finding stocks trading below their estimated intrinsic values can be a prudent strategy for those looking to capitalize on potential market inefficiencies.
High Growth Tech Stocks To Watch In The Global Market
Global markets have been buoyed by optimism surrounding a potential U.S.-Iran peace agreement, with major U.S. stock indexes like the Nasdaq Composite and Russell 2000 reaching record highs, driven in part by enthusiasm for AI-linked stocks. In this environment of rising investor sentiment and technological momentum, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on advancements in artificial intelligence and other innovative...